Vyvanse Capsules CII administration through 2 routes demonstrated similar pharmacokinetic profile
Thursday, October 22, 2009 - 18:21
in Health & Medicine
PHILADELPHIA -- October 22, 2009 -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced new data about the pharmacokinetics of its Attention-Deficit/Hyperactivity Disorder (ADHD) medication, Vyvanse® (lisdexamfetamine dimesylate) Capsules CII, which showed that Vyvanse provided similar concentrations of its active medication in the blood when adminis